Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Overview
Explore Kiniksa Pharmaceuticals, Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Kiniksa Pharmaceuticals, Ltd. (KNSA)
Key Financials
Key Financials
Market Cap
3.7B
P/E Ratio
51.27
EPS (TTM)
$0.91
ROE
0.13%
KNSA Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Kiniksa Pharmaceuticals, Ltd. (KNSA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 41.52, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $59.23.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 51.27 and a market capitalization of 3.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.